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Policy Forum
I
n 2002, Plasmodium falciparum 
caused at least 0.5 billion 
uncomplicated clinical attacks of 
malaria worldwide, particularly in non-
immune young children living in Africa 
[1]. Because inadequately treated 
uncomplicated P. falciparum malaria 
can progress rapidly to life-threatening 
severe malaria [2,3], mortality from 
P. falciparum in Africa doubled during 
the 1990s against a rising frequency of 
resistance to commonly used drugs, 
such as chloroquine and sulfadoxine-
pyrimethamine [4].
In recent years, the deployment 
of highly efficacious oral three-
day regimens of artemisinin-based 
combination therapies (ACTs) with 
parasitological cure rates of 95% or 
greater in more than 40 endemic 
countries has radically changed 
antimalarial treatment [5–8]. This 
success demands a new approach 
to the ways in which we assess new 
antimalarial drugs during clinical 
development and judge their 
potential utility for the public health 
deployment [9]. For example, the 
ability of slowly eliminated new 
drugs to delay re-infections and thus 
secondary malaria episodes for several 
weeks by suppressing the growth of P. 
falciparum provides additional public 
health benefits, especially in high-
transmission areas where re-infection 
rates can exceed 50% in less than six 
weeks [10,11]. In turn, new drugs with 
comparatively higher efficacy against 
primary blood stage infections and/or 
a shorter elimination half-life minimise 
morbidity from recrudescent primary 
infections and may reduce the rate of 
spread of resistance [9,12], and are 
thus particularly valuable in situations 
of low or decreasing transmission 
rates [13] where the likelihood of 
re-infection during the relatively 
short post-treatment prophylactic 
period is lower (Figure 1A and 1B). 
There is already a general consensus 
on the design and interpretation of 
clinical trials used for monitoring 
antimalarial drug efficacy by national 
malaria control programmes [14]. The 
objective of this paper is to reflect on 
the design and interpretation of phase 
III trials. 
Defining the Primary Endpoint
In the era of highly efficacious ACTs 
there is considerable debate among 
experts on what, exactly, constitutes 
the most relevant property of a new 
antimalarial drug [9,15]. In other 
words, in phase III trials, should we ask:
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Summary Points
sÈ #URINGÈMALARIAÈEPISODESÈISÈTHEÈKEYÈ
priority for antimalarial treatment; its 
measurement as primary endpoint 
in phase III trials provides consistent 
estimates of the antiparasitic effect of a 
new regimen.
sÈ 4HEÈDELAYÈOFÈSECONDARYÈMALARIAÈ
episodes by slowly eliminated new 
drugs provides additional public 
health benefits in high-transmission 
areas; it should therefore be measured 
as key secondary or, preferably, co-
primary endpoint.
sÈ 7(/ÈSUGGESTSÈAIMINGÈTOÈACHIEVEÈ
parasitological cure rates of ≥95%; if 
adopted for drug development this 
sets a high bar and may lead to the 
premature rejection of potentially 
valuable new drugs.
sÈ 3INCEÈSMALLÈDIFFERENCESÈINÈCUREÈ
rates of ≥95% may be outweighed 
by advantages in cost, dosing, 
or tolerability, new drugs can be 
examined in non-inferiority trials with 
a proposed difference margin of ≤5%.
sÈ 7EÈRECOMMENDÈSURVIVALÈANALYSISÈOFÈTHEÈ
primary endpoint.PLoS Medicine  |  www.plosmedicine.org 1547 November 2008  |  Volume 5  |  Issue 11  |  e227
1. How efficacious is the new drug in 
curing primary blood stage infections 
(chemotherapeutic efficacy)?
 or
2. How efficacious is the new regimen 
in curing primary infections and 
in preventing secondary infections 
(composite chemotherapeutic 
and post-treatment prophylactic 
efficacy)?
 or 
3. How efficacious is the new drug 
in reducing the post-treatment 
incidence of malaria and its 
complications (clinical risk 
reduction)?
Whilst the scientific question being 
asked determines the definition of 
the primary endpoint, it is important 
to understand that the measure of 
drug efficacy by any of these three 
endpoints is, to a variable extent, 
determined by factors unrelated to 
the intrinsic antiparasitic effects of 
antimalarial treatment regimens. 
Extensive inter-population variation 
in levels of acquired host immunity 
[16] and parasite re-infection rates 
[10,17] complicates the interpretation 
and comparison of results from 
different geographical areas or 
between sites in multicentre phase 
III trials [18]. Pharmacogenetic 
differences have not been shown 
to play a major role in the variation 
in therapeutic response (although 
there are relatively few studies), but 
pharmacokinetic differences related 
to age and pregnancy have been large, 
and clinically important for several 
antimalarials [19]. This is a concern 
for malaria control programmes in 
endemic countries and agencies that 
fund drug purchases, both of whom 
require comparability of clinical 
trial outcomes to weigh the relative 
advantages of new antimalarial drugs 
as they emerge from the clinical 
development pipeline (phases I–IV; 
Figure 2).
1. Cure of primary malaria episodes 
and infections. The chemotherapeutic 
efficacy of an antimalarial drug 
against primary malaria episodes can 
be estimated by the established “in 
vivo test” methodology [20]. This 
test observes two key events. The first 
criterion is the alleviation of clinical 
symptoms and the suppression of the 
density of the pathogenic asexual 
blood stage parasites in the peripheral 
blood below the light-microscopic 
detection threshold (around 20–50 
parasites/µl) within the first few days 
(avoiding “early treatment failure”). 
The second event is the potential 
recrudescence of persistent asexual 
blood stage parasites after one week 
(“late parasitological treatment 
doi:10.1371/journal.pmed.0050227.g001 
Figure 1. Simulated Plots of Weekly Incidence Rates and Cumulative Proportions for 
Recrudescent Primary Infections and Re-Infections Following Treatment of Uncomplicated P. 
falciparum Malaria with a Slowly Eliminated (Partner) Drug (Half-Life of ~1 Week)
The solid line represents recrudescent infections with a cumulative failure rate of 5% by day 42. 
Dashed lines represent different rates of re-infections corresponding to entomological inoculation 
rates of two (yellow), four (orange), and six (red) infective mosquito bites/year, respectively. 
Trailing plasma drug concentrations delay both detectable recrudescent primary and secondary 
blood stage infections—however, both effects are fading until day 42. Figure 1A illustrates that 
most recrudescent primary infections are captured by day 42. Extension of follow-up beyond 
day 28 results in increased ratios of new versus recrudescent infections and hence, elevated risk 
of outcome misclassifications due to intrinsic limitations of current molecular techniques used 
to discriminate between primary and secondary infections. The assessment of the total number 
of recurrent infections as a composite outcome (often denoted the PCR “uncorrected cure 
rate”) requires some time limits as re-infection occurs eventually in almost everyone after blood 
concentrations of the drug(s) fall below the MIC (Figure 1B).PLoS Medicine  |  www.plosmedicine.org 1548 November 2008  |  Volume 5  |  Issue 11  |  e227
failure”) (Figure 1A), which may or 
may not be associated with clinical 
symptoms of malaria (“late clinical 
treatment failure”) [18,20]. In 
the absence of re-infection, and 
assuming adequate drug absorption, 
the incidence of and the time to the 
microscopic detection of recrudescent 
blood stage infections has been 
shown to be primarily a function of 
(1) variability in pharmacodynamic 
variables, i.e., parasite susceptibility 
and initial parasite biomass; (2) 
pharmacokinetic parameters, i.e., 
drug elimination kinetics; and also (3) 
drug-unrelated parameters, primarily 
the patients’ immune status [16,20–
23].
As many drugs have no effects 
on pre-erythrocytic (liver stage) 
development, new blood stage 
infections may become patent 
as early as one week after blood 
concentrations of the antimalarial 
drug fall below the minimum 
inhibitory concentration (MIC) 
[24]. This situation requires 
molecular fingerprinting techniques 
to determine the likely origin 
of the parasite strain(s) in the 
recurrent infection and hence, to 
separate chemotherapeutic failures 
(recrudescence of the primary 
infection) from reinfection (Figure 
1A) [14]. Since even a single 
misclassification can significantly 
change the risk difference between 
test and reference arms at cure 
rate estimates of at least 95%, the 
issue of accuracy of parasite strain 
genotyping (“PCR correction”) has 
attracted considerable attention 
[9,25–29]. The controversy centres 
on the very real risk that a variable 
proportion of recurrent infections 
may either (1) be misclassified 
leading to underestimation or 
(less likely) overestimation of cure 
rates or (2) remain indeterminate 
(unclassifiable) [29,30], especially 
in high-transmission areas when 
follow-up periods extend past day 
28 (Figure 1A) [25–28]. There are 
also unresolved issues related to 
relapses of P. vivax infections in Asia 
[31]. Even so, re-infection-adjusted 
parasitological cure rates provide 
demonstrably consistent estimates 
of the antiparasitic effect of an 
antimalarial regimen across different 
transmission settings [10,17], and 
the World Health Organization 
(WHO) endorses PCR-corrected 
primary endpoints for monitoring 
antimalarial drug efficacy in endemic 
countries [14,32]. At the same time, 
the exclusion or censoring of all re-
infections limits the clinical relevance 
of chemotherapeutic endpoints in 
high-transmission areas (Figure 1B).
2. Cure of primary infections 
and prevention of re-infections. Of 
course, any recurrent infection can 
be considered a failure, as even new 
infections reflect a post-treatment 
“chemoprophylaxis” breakthrough 
(Figure 1A) [33]. Frequently, this 
effect has been assessed by using the 
proportion of the total number of 
recurrences as a composite endpoint 
without distinguishing between 
recrudescent primary and secondary 
infections (or for that matter, curative 
and preventive effects) [15,34]. But 
since re-infection occurs eventually 
in almost everyone after blood 
concentrations of the drug(s) fall 
below the MIC, the measurement of 
the composite endpoint requires some 
time limits.
In high-transmission areas, the 
composite effect size will largely be 
determined by the post-treatment 
prophylactic efficacy against secondary 
infections [10]. The duration of this 
protection depends on the ability of 
the drug to suppress the clinically 
silent intra-hepatocytic parasite 
development and on the elimination 
half-life of the drug (Figure 1A) 
[33]. The problem with assessing the 
composite outcome (often denoted 
the PCR “uncorrected cure rate”) 
alone is that it combines two effects 
(curative activity and post-treatment 
prophylaxis) that, although related, are 
not directly proportional to each other 
(Figure 1B). To illustrate this point, 
the reported crude, PCR-uncorrected 
parasitological day 28 failure rates in 
two trials of the recently registered 
six-dose regimen of artemether-
lumefantrine can be compared. These 
rates differed by 25% whereas the 
corresponding parasitological cure rate 
estimates adjusted for the difference 
in re-infection rates varied by only 7% 
[10,17]. The interpretation of such large 
inter-site variations poses a problem in 
rigorous and costly phase III programs 
where the reproducibility of what 
the phase III trial set out to measure, 
i.e., the antiparasitic effect of the new 
regimen, is a prime concern [14].
doi:10.1371/journal.pmed.0050227.g002 
Figure 2. Simplified Outline of the Iterative Process of the Clinical Development of New 
Antimalarial Candidate Drugs or Drug Combinations
Phase III trials are designed to provide pivotal efficacy and safety data for obtaining regulatory 
approval. The indicated numbers of study participants are approximations of the magnitude of 
required total sample sizes in different transmission settings.PLoS Medicine  |  www.plosmedicine.org 1549 November 2008  |  Volume 5  |  Issue 11  |  e227
3. Post-treatment reduction of 
clinical risk. Recrudescent primary 
infections, as well as re-infections, 
entail the risk of secondary malaria 
and/or hematological complications 
requiring re-treatment [34,35]. 
Clinical endpoints, which measure 
the reduction of these clinical 
events, provide important public 
health–relevant information above 
parasitologically defined endpoints 
[15,36,37].
The risk that a patient with 
recurrent infection will be 
symptomatic at detection or succumb 
subsequently to secondary malaria 
during follow-up is related to 
the individual level of specific, if 
imperfect, acquired immunity (“semi-
immunity”). For example, an analysis 
of antimalarial treatment trials in 
high-transmission areas found that 
children below one year were at least 
three times as likely to experience 
symptomatic recurrences than 
children aged more than three years 
[34]. This dependence of clinical 
risks on the prevalence of acquired 
immunity in the study population or 
age group [18,34] (on top of large 
variation introduced by different re-
infection/recurrence rates) confounds 
the estimation of the antiparasitic 
efficacy of an antimalarial drug by 
clinical endpoints, and therefore 
undermines the comparability of study 
results between different endemic 
areas, leading to large inter-site 
variation in multicentre phase III trials 
[18]. Alternatively, preliminary data 
from study sites on key confounding 
factors could, in conjunction with 
normalisation provided by a standard 
comparator treatment, be used to 
adjust for inter-site differences in trials 
with a primary clinical endpoint. The 
feasibility of such an adjusted primary 
analysis approach in regulatory phase 
III trials needs to be explored further.
Based on the above considerations, 
whilst it is clear that, in areas of very 
high transmission, multiplicity of 
infection confers a significant and 
irreducible error in genotyping [38], 
parasite “strain typing” with the 
highest possible resolution power 
is required for separating curative 
and preventive effects in regulatory 
phase III trials of new antimalarial 
drugs. Chemotherapeutic efficacy 
against primary malaria episodes 
and infections should be the primary 
endpoint of phase III trials; protective 
efficacy against secondary infections 
and clinical episodes should be either 
key secondary endpoints, or in high-
transmission areas, possibly co-primary 
endpoints. A broad consultation on 
the utility, classification, and respective 
merits of alternative, especially PCR-
uncorrected, composite endpoints 
in phase III trials of new antimalarial 
drugs, including measurement of 
the delay instead of proportions 
of recurrent infections, should be 
undertaken.
Defining the Benchmark for 
Efficacy
Optimal target profiles for new 
antimalarial drugs have been 
described elsewhere and used as 
guiding principles from early discovery 
through clinical development [39,40]. 
In an ideal world, antimalarial 
treatments would be 100% efficacious; 
in the real world, WHO suggests 
aiming to achieve parasitological cure 
rate point estimates of at least 95% 
(excluding re-infections) [41]. To 
establish with 95% confidence that a 
new treatment can demonstrate a cure 
rate of at least 95% in a phase III trial 
with 500 patients per group, the true 
(unknown) cure rate would have to 
be at least 97%. This sets a high bar 
for evaluating new candidate drugs 
and might lead to the premature 
rejection of new products because of 
suboptimal dosing, formulation, or 
the play of chance. A greater than 
90% parasitological cure rate (lower 
boundary of the 95% confidence 
interval) represents an alternative, 
more realistic initial target for new 
treatments (requiring only a true cure 
rate of at least 93% under the same 
sample size assumption).
To date, there is no guidance on 
the benchmark for the protective 
efficacy of a new antimalarial drug in 
preventing secondary infections, or 
the composite efficacy of curative and 
preventive effects. The establishment 
of a uniform benchmark is challenging: 
in addition to clearing more than 
90% of primary infections, should a 
new drug prevent 30%, 40%, or more 
of secondary infections? Over which 
time frame—four, six, or more weeks? 
Or, put more simply, for how long 
on average should re-infections or, 
more generally, recurrent infection 
be delayed? Should the new drug 
be superior to or “just as good as” 
the reference treatment? Or to use 
Table 1. Potential Outcome Scenarios of Antimalarial Phase III Trials with a Chemotherapeutic Endpoint and Their Proposed Interpretation
95% CI on
Hazard Ratio (Test/Control) Below  
Non-Inferiority Limit
Test Drug More Than 90% Survival 
Estimate by Day 28 or Later
Default Rate Less Than 10% 
(Excluding Censored New Infections)
Interpretation
Yes Yes Yes Positive trial
Yes Yes No Indeterminate
Yes Noa Yes Indeterminate
Yes No No Indeterminate
No Yes Yes Positive trial
No Yes No Indeterminate
No No Yes Negative trial
No No No Negative trial
“Indeterminate” results prompt a careful analysis of trial-related inadequacies, especially in case of trials that demonstrate the non-inferiority of the new treatment but fall short of the 
over 90% criterion. There is also need for caution when applying the over 90% criterion to studies from high-transmission areas because of the potential of current parasite genotyping 
protocols to overestimate failure rates. The integration of population pharmacokinetic analysis may facilitate the interpretation of negative trial results by quantifying the relationship 
between plasma drug levels and failures [53].
aIf the lower limit of the 95% CI calculated around the survival estimate in the reference treatment arm also crosses below 90% (possibly indicating overestimation of failure rates in both 
test and reference arms), the trial can be considered as positive.
doi:10.1371/journal.pmed.0050227.t001PLoS Medicine  |  www.plosmedicine.org 1550 November 2008  |  Volume 5  |  Issue 11  |  e227
a hypothetical example, in times 
of continued shortage of viable 
therapeutic options, is it desirable to 
turn down a new once-daily regimen 
with a composite efficacy comparable 
to the recently introduced twice-daily 
regimen of artemether-lumefantrine, 
but which may be inferior to 
dihydroartemisinin-piperaquine 
because piperaquine is exceptionally 
slowly eliminated [10,42,43]? All this 
needs to be considered in a context 
of declining malaria transmission as 
effective control measures are rolled 
out. There is currently no consensus on 
these issues.
Duration of Follow-Up
Figure 1A illustrates how trailing 
plasma drug concentrations of slowly 
eliminated antimalarial drugs delay 
detectable recrudescent primary and 
secondary blood stage infections alike. 
These effects fade during follow-up 
beyond day 28.
The current use of day 28 estimates 
provides a single benchmark period 
to compare all new drugs, but we 
feel there is a need to revisit this 
single time-point for phase III trial 
endpoints, particularly for new 
investigational drugs or combinations 
containing at least one component 
with an intrinsically long plasma half-
life.
Superiority or Non-Inferiority?
In phase III, the new candidate drug is 
compared in a randomised controlled 
trial [44] to a standard treatment that 
retains the desired “control effect size” 
[44], e.g., the targeted more than 90% 
parasitological cure rate (excluding re-
infections). Historically, when existing 
recommended treatments were failing, 
antimalarial phase III drug trials have 
been designed as superiority trials 
[9,45], but there is a dramatic increase 
in the sample sizes required to 
demonstrate superiority of a potential 
future replacement for a drug with 
currently very high parasitological 
cure rates [9].
Small differences in parasitological 
cure rates demonstrated in superiority 
trials, especially between 95% and 
100%, are important in reducing the 
emergence and spread of resistance 
[9,12], but from a pragmatic 
perspective such differences may be 
outweighed by advantages in cost, 
dosing, shelf lives, or tolerability, 
or importantly, by the gain of a 
therapeutic alternative should parasite 
resistance to the current first-line 
drug emerge. An alternative to the 
superiority criterion for a new drug 
is whether it is “no worse than” 
the standard treatment [9]. Non-
inferiority trials test if the observed 
difference between treatment arms 
falls below a difference ∆ margin; if 
not, the new treatment is considered 
non-inferior [46]. The ∆ margin is 
selected to ensure that a drug with 
clinically meaningful inferiority to 
the comparator treatment is rejected 
[47]. We propose to use a ∆ margin of 
5%, or its equivalent as hazard ratio 
limit, within the limits of cure rates 
exceeding 90%.
The superiority of the post-treatment 
prophylactic efficacy of a new drug 
with comparatively higher anti-liver 
stage activity or prolonged plasma 
half-life can be best examined in 
areas with high re-infection rates 
because of the postulated differential 
impact on re-infection and/or 
secondary malaria rates [33]. The 
comparison to a reference treatment 
with similar pharmacodynamic and 
pharmacokinetic characteristics, 
however, requires inflated sample sizes 
in high-transmission areas.
Analytical Strategies
Intention-to-treat versus per-
protocol approach. The transition 
from superiority to non-inferiority 
trial designs has implications for 
the choice of the primary analysis 
population [48]. Non-inferiority 
trials lack internal controls for 
assessment accuracy, a conservative 
analysis approach, and protection 
from bias by blinding [9]. Technical 
and methodological inadequacies, 
e.g., missing or uninterpretable 
PCR data in an intention-to-treat 
analysis (considered as conservative in 
superiority trials), or simple mistakes 
can blur true differences in treatment 
effects and thus lead to inadvertent 
conclusion of non-inferiority when in 
fact the new drug is inferior (type I 
error) [46,49]. On the other hand, 
indiscriminate classification of 
defaulting patients as failures in the 
intention-to-treat analysis (“worst-case 
scenario”), particularly losses to follow-
up or re-infections when recrudescent 
rates or time to recrudescence are 
the primary endpoint, reduces the 
power of non-inferiority trials and 
thus leads to incorrect finding of 
inferiority when in fact the new drug 
is not inferior (type II error). If the 
primary endpoint is measured as 
proportional point estimate (i.e., not 
by survival analysis), we recommend 
basing the analysis on the per-protocol 
population, which includes only 
patients with observed treatment 
responses and other informative 
outcomes, e.g., intake of outside-
protocol antimalarial medication. 
The preferred method for comparing 
antimalarial drug efficacy, however, is 
survival analysis [9]. 
Survival analysis. Survival analysis 
techniques are increasingly used to 
assess failure rates in randomised phase 
III trials [49]. The key advantages 
of this approach for antimalarial, or 
any other anti-infective drug studies, 
are: (1) the statistical model reflects 
specific biological processes (delay of 
recrudescence or re-infection [20]) 
and (2) the analytical procedure 
deals specifically with incomplete but 
informative data, i.e., patients with 
incomplete follow-up contribute to the 
assessment, whereas they are excluded 
in per-protocol analyses [9,50]. Re-
infections, losses to follow-up, and 
protocol deviations can be censored 
at the time of defaulting. Analogous 
to tests of the risk difference of point 
estimates [37], the non-inferiority 
hypothesis of survival estimates can 
be examined by using a modified 
confidence interval (CI) approach 
[51].
Interpretation of Trial Results
The interpretation of a non-inferiority 
trial with a survival estimate of 
recrudescent infections can be based 
on two criteria: (1) the hypothesis 
test result, e.g., the 95% CI of the 
proportional hazard ratio test/control 
remains below the non-inferiority 
limit on the hazard ratio to support 
claims of efficacy [51]; and (2) the 
day 28 and later survival rate estimate 
Linked Perspective 
This Policy Forum is further discussed 
in a PLoS Medicine Perspective by Colin J. 
Sutherland:
Sutherland CJ (2008) Comparing highly 
efficacious antimalarial drugs. PLoS 
Med 5(11): e228. doi:10.1371/journal.
pmed.0050228PLoS Medicine  |  www.plosmedicine.org 1551 November 2008  |  Volume 5  |  Issue 11  |  e227
in the test drug arm. Table 1 lists 
possible combinations of trial results 
and recommendations for their 
interpretation. The standardised 
reporting of key baseline and outcome 
variables of antimalarial trials using a 
hierarchical system will greatly facilitate 
further detailed post-hoc analyses and 
interpretations [18].
Conclusion
Consensus-agreed regulatory guidelines 
on how phase III trials of antimalarial 
drugs for uncomplicated P. falciparum 
malaria are designed and interpreted 
are only now being developed [52]. 
This review intends to stimulate an 
informed discussion on the utility of 
the different primary endpoints in 
future phase III antimalarial trials and 
proposes a comparative framework 
for the interpretation of results from 
ongoing trials. We hope that consensus 
between academia, public health 
professionals, industry, and regulators 
on the design and particularly the 
primary endpoint of phase III trials 
allows earlier appraisal of the potential 
advantages or equivalence of a new 
treatment in comparison with existing 
therapies ahead of more extensive 
phase IV programmes.  
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